Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/41440
Authors: 
Kaiser, Ulrich
Mendez, Susan J.
Rønde, Thomas
Year of Publication: 
2010
Series/Report no.: 
ZEW Discussion Papers 10-062
Abstract: 
On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate the joint effects of this reform on prices and quantities. Prices decreased more than 26 percent due to the reform, which reduced patient and government expenditures by 3.0 percent and 5.6 percent, respectively, and producer revenues by 5.0 percent. The prices of expensive products decreased more than their cheaper counterparts, resulting in large differences in patient benefits from the reform.
Subjects: 
pharmaceutical markets
regulation
co-payments
reference pricing
asymmetric welfare effects
JEL: 
I18
C23
Document Type: 
Working Paper

Files in This Item:
File
Size
446.79 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.